Page last updated: 2024-12-07

nitisinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Nitisinone, also known as NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione), is a potent and specific inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (4-HPPD). 4-HPPD is a key enzyme in the biosynthesis of tyrosine, a precursor to melanin, a pigment found in skin, hair, and eyes. Nitisinone inhibits the activity of 4-HPPD, preventing the production of melanin. This compound is used to treat the genetic disorder hereditary tyrosinemia type 1 (HT-1), a metabolic disease that causes a buildup of tyrosine in the body. Nitisinone is effective in reducing the levels of tyrosine and its toxic byproducts, which can cause liver failure, kidney failure, and neurologic damage. Nitisinone is also being studied for its potential use in treating other disorders, such as albinism and cancer. It is thought that nitisinone could be used to reduce the production of melanin in these disorders, thereby reducing the risk of skin cancer and other complications. Nitisinone is a promising therapeutic agent that has shown significant efficacy in the treatment of HT-1. Its potential applications in other disorders are currently under investigation.'

Cross-References

ID SourceID
PubMed CID115355
CHEMBL ID1337
CHEBI ID50378
SCHEMBL ID338795
SCHEMBL ID15996621
MeSH IDM0207118

Synonyms (88)

Synonym
BIDD:PXR0129
N1054
2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione
ntbc
c14h10f3no5
nitisinone [inn]
nitisone
orfadin
sc 0735
1,3-cyclohexanedione, 2-(2-nitro-4-(trifluoromethyl)benzoyl)-
nitisinone [usan:inn]
CHEBI:50378 ,
nitisinonum
nitisinona
2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
104206-65-7
D05177
orfadin (tn)
nitisinone (jan/usan/inn)
nitisinone ,
DB00348
2-(alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
bdbm50088804
CHEMBL1337 ,
sc-0735
2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione;nitisinone
A800922
NCGC00185778-01
EX-6233
2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione
ntbc cpd
smr002529592
MLS004774025
unii-k5bn214699
k5bn214699 ,
AKOS015994590
AM62666
1,3-cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]-
FT-0672739
NCGC00185778-02
AKOS015891363
S5325
RB3134
gtpl6834
nitisinone [usan]
nitisinone [orange book]
nitisinone [vandf]
nitisinone [mi]
nitisinone [jan]
nitisinone [who-dd]
nitisinone [ema epar]
nityr
nitisinone [mart.]
2-(.alpha.,.alpha.,.alpha.-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
CCG-222085
HY-B0607
SCHEMBL338795
MLS006011955
FE-0200 ,
SCHEMBL15996621
DTXSID9042673
AC-26934
2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione
mfcd01752192
sc0735
sr-01000940576
SR-01000940576-2
nitisinone, >=95% (hplc)
J-505680
Q3877355
Z1172207721
BCP15276
ntbc; nitisone; sc0735; sc 0735; sc-0735
SB19017
HMS3870K03
NCGC00185778-07
HMS3740A15
NCGC00185778-04
2-(2-nitro-4-(trifluoromethyl)-benzoyl)cyclohexane-1,3-dione
SY047291
nsc773149
nsc-773149
oubcnlgxqfstlu-uhfffaoysa-n
nitisinone (mart.)
a16ax04
EN300-123436

Research Excerpts

Overview

Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase (4HPPD) It is a relatively new agent that is currently recommended for the medical management of the disease.

ExcerptReferenceRelevance
"Nitisinone is a beneficial therapy in Alkaptonuria."( Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
Barton, GJ; Briggs, M; Cox, TF; Daroszewska, A; Davison, AS; Devine, JM; Dillon, JP; Fisher, M; Gallagher, JA; Griffin, R; Harrold, J; Hughes, AT; Hughes, G; Jarvis, JC; Jones, A; Judd, S; Khedr, M; Loftus, N; McCormick, M; Milan, AM; Psarelli, EE; Ranganath, LR; Sireau, N; Taylor, S; Usher, JL; Vinjamuri, S; West, E, 2018
)
3.37
"Nitisinone is a relatively new agent that is currently recommended for the medical management of the disease."( Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients.
Aydogdu, S; Farajov, R; Iakobadze, Z; Karaca, CA; Kilic, M; Yilmaz, C, 2019
)
1.24
"Nitisinone is a remarkable safe drug to use with few side effects reported."( The role of nitisinone in tyrosine pathway disorders.
Lock, E; Ranganath, LR; Timmis, O, 2014
)
1.5
"Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase (4HPPD). "( [New drugs; nitisinone].
Cohen, AF; van Bronswijk, H, 2006
)
2.16

Effects

Oral nitisinone has been shown to increase fur and ocular pigmentation in a mouse model of oculocutaneous albinism. Treatment has opened new horizons in the management of type 1 tyrosinemia, but LT still remains the only option for the patients developing LF and in the event of HCC.

ExcerptReferenceRelevance
"Nitisinone has been approved for treatment of alkaptonuria (AKU). "( Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients.
Bay-Jensen, AC; Frederiksen, P; Gallagher, JA; Genovese, F; Karsdal, MA; Milan, AM; Olsson, B; Ranganath, LR; Rudebeck, M, 2023
)
3.8
"Oral nitisinone has been shown to increase fur and ocular pigmentation in a mouse model of oculocutaneous albinism (OCA) due to hypomorphic mutations in tyrosinase (TYR), OCA1B. "( Minimal Efficacy of Nitisinone Treatment in a Novel Mouse Model of Oculocutaneous Albinism, Type 3.
Abu-Asab, MS; Adams, DR; Aderemi, JO; Albert, JS; Alur, RP; Bernardini, IM; Brooks, BP; Chan, CC; Cogliati, T; Megan, LH; Melch, MG; Onojafe, IF, 2018
)
1.32
"Nitisinone treatment has opened new horizons in the management of type 1 tyrosinemia, but LT still remains the only option for the patients developing LF and in the event of HCC."( Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients.
Aydogdu, S; Farajov, R; Iakobadze, Z; Karaca, CA; Kilic, M; Yilmaz, C, 2019
)
1.24
"Nitisinone has transformed the management of hereditary tyrosinaemia type 1 (HT1). "( Outcome of children with hereditary tyrosinaemia following newborn screening.
Chakrapani, A; McKiernan, PJ; Preece, MA, 2015
)
1.86
"Nitisinone has revolutionized the management of TTI but its effect on renal tubular dysfunction has not been described in a large cohort of patients."( Renal tubular function in children with tyrosinaemia type I treated with nitisinone.
Hulton, SA; McKiernan, PJ; Preece, MA; Santra, S, 2008
)
1.3
"Nitisinone has significantly improved outcome and quality of life in HT type I; however, it is also accompanied by elevated plasma and CSF tyrosine."( Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.
Assmann, B; Herebian, D; Klee, D; Mayatepek, E; Spiekerkoetter, U; Thimm, E, 2011
)
1.09
"Nitisinone has transformed the natural history of tyrosinaemia."( Nitisinone in the treatment of hereditary tyrosinaemia type 1.
McKiernan, PJ, 2006
)
2.5

Actions

ExcerptReferenceRelevance
"Nitisinone produced an increase in tyrosine and catecholamine metabolite (HVA, VMA, and metanephrines) levels."( Response of metastatic recurrent neuroblastoma to nitisinone: a modulator of tyrosine metabolism.
Kobrinsky, NL; Sjolander, DE, 2006
)
1.31

Treatment

Nitisinone treatment has opened new horizons in the management of type 1 tyrosinemia, but LT still remains the only option for the patients developing LF.

ExcerptReferenceRelevance
"Nitisinone treatment induced changes in biomarkers of bone and cartilage remodelling."( Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients.
Bay-Jensen, AC; Frederiksen, P; Gallagher, JA; Genovese, F; Karsdal, MA; Milan, AM; Olsson, B; Ranganath, LR; Rudebeck, M, 2023
)
3.07
"Nitisinone-treated AKU mice were fed tyrosine/phenylalanine-free and phenylalanine-free diets with phenylalanine supplementation in drinking water."( Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Bou-Gharios, G; Gallagher, JA; Hughes, AT; Hughes, JH; Jarvis, JC; Judd, S; Milan, AM; Ranganath, LR; Sutherland, H; Wilson, PJM, 2020
)
1.5
"Nitisinone treatment resulted in an approximately 7-fold increase in plasma tyrosine concentrations without overt toxicity."( Minimal Efficacy of Nitisinone Treatment in a Novel Mouse Model of Oculocutaneous Albinism, Type 3.
Abu-Asab, MS; Adams, DR; Aderemi, JO; Albert, JS; Alur, RP; Bernardini, IM; Brooks, BP; Chan, CC; Cogliati, T; Megan, LH; Melch, MG; Onojafe, IF, 2018
)
1.53
"Nitisinone treatment has opened new horizons in the management of type 1 tyrosinemia, but LT still remains the only option for the patients developing LF and in the event of HCC."( Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients.
Aydogdu, S; Farajov, R; Iakobadze, Z; Karaca, CA; Kilic, M; Yilmaz, C, 2019
)
1.24
"Nitisinone treatment reduced plasma HGA in AKU mice throughout their lifetime, and completely prevented pigment deposition."( Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
Gallagher, JA; Jarvis, JC; Keenan, CM; Preston, AJ; Ranganath, LR; Sutherland, H; Taylor, AM; Williams, DP; Wilson, PJ; Wlodarski, B, 2014
)
1.35
"Nitisinone treatment is effective and improves both short- and long-term prognosis of HT1. "( Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Altay, S; Aydin, A; Cansever, S; Erkan, T; Kiykim, E; Soyucen, E; Zeybek, AC; Zubarioglu, T, 2015
)
1.86
"Only nitisinone-treated Tyrc-h/c-h mice manifested increased pigmentation in their fur and irides and had more pigmented melanosomes."( Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.
Adams, DR; Alur, RP; Bernardini, IM; Brilliant, MH; Brooks, BP; Chan, CC; Dolinska, MB; Gahl, WA; Onojafe, IF; Sergeev, YV; Simeonov, DR; Zhang, J, 2011
)
2.27
"Nitisinone treatment abolishes the acute complications of HT1. "( Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Alvarez, F; Bussières, JF; Chevalier, I; Dallaire, L; Dubois, J; Faucher, F; Fenyves, D; Goodyer, P; Grenier, A; Holme, E; Laframboise, R; Lambert, M; Larochelle, J; Lindstedt, S; Maranda, B; Melançon, S; Merouani, A; Mitchell, GA; Mitchell, J; Parizeault, G; Pelletier, L; Phan, V; Rinaldo, P; Scott, CR; Scriver, C, 2012
)
2.22
"Treatment with nitisinone (NTBC) has brought about a drastic improvement in the treatment and prognosis of hereditary tyrosinemia type I (HT1). "( Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
Aldámiz-Echevarría, L; Bueno, M; Couce, ML; Díaz-Fernández, C; García-Volpe, C; Gil, D; Hernández, T; López-Ruzafa, E; Martín-Hernández, E; Navas, V; Peña-Quintana, L; Pintos, G; Roca, I; Sánchez-Pintos, P; Sánchez-Valverde, F; Vitoria, I, 2019
)
1.1
"Treatment with nitisinone has improved the prognosis of HT1, and compliance is good. "( Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
Aldámiz-Echevarría, L; Couce, ML; Dalmau, J; del Toro, M; Pintos-Morell, G, 2011
)
0.72

Toxicity

ExcerptReferenceRelevance
" The primary endpoints, occurrence of adverse events related to hepatic, renal, ophthalmic, haematological, or cognitive or developmental function, were assessed in the complete set (all patients already receiving treatment at the index date [Feb 21, 2005] or starting treatment thereafter) and the index set (the subset of patients who had their first dose on the index date or later only)."( Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Couce, ML; Das, AM; de Laet, C; Dionisi-Vici, C; Lund, AM; Rudebeck, M; Schiff, M; Spada, M; Sparve, E; Spiekerkoetter, U; Szamosi, J; Vara, R, 2021
)
0.86
" Incidences of hepatic, renal, ophthalmic, haematological, or cognitive or developmental adverse events were low."( Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Couce, ML; Das, AM; de Laet, C; Dionisi-Vici, C; Lund, AM; Rudebeck, M; Schiff, M; Spada, M; Sparve, E; Spiekerkoetter, U; Szamosi, J; Vara, R, 2021
)
0.86

Bioavailability

ExcerptReferenceRelevance
" In the first study, the relative bioavailability of NTBC from liquid and capsule formulations was compared and the effect on plasma tyrosine concentrations measured."( Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
Eksborg, S; Hall, MG; Lumholtz, B; Provan, WM; Wilks, MF, 2001
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1) was an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study.

ExcerptRelevanceReference
" Analysis of the key hepatic enzymes involved in tyrosine catabolism, following a single dose of 30 micromol NTBC/kg, showed that 4-hydroxyphenylpyruvate dioxygenase (HPPD) was markedly inhibited soon after dosing and that the activity recovered very slowly."( Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.
Ellis, MK; Gaskin, P; Lock, EA; McLean Provan, W; Robinson, M; Smith, LL, 2000
)
0.31
" At the recommended average dosage (1 mg kg(-1)), liver failure improved transiently."( Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
Bodamer, OA; Crone, J; Holme, E; Huber, WD; Möslinger, D; Schima, W; Stöckler Ipsiroglu, S, 2003
)
0.32
"In HTI patients with a poor response to NTBC treatment and/or development of cirrhotic changes of liver parenchyma, augmentation of the recommended NTBC dosage may result in significant improvement of symptoms."( Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
Bodamer, OA; Crone, J; Holme, E; Huber, WD; Möslinger, D; Schima, W; Stöckler Ipsiroglu, S, 2003
)
0.32
"05 mg bid, and remained on this dosage and a regular diet for 3 months."( Use of nitisinone in patients with alkaptonuria.
Bernardini, I; Gahl, WA; Gerber, LH; Kaiser-Kupfer, MI; O'Brien, K; Perry, MB; Rubin, BI; Sebring, N; Suwannarat, P; Tsilou, E, 2005
)
0.78
" NTBC dosage should be reduced to the minimal dose allowing metabolic control, once daily dosing may be an option in older children and adults in order to increase compliance."( Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Aldamiz-Echevarria, LJ; Bliksrud, YT; Brunner-Krainz, M; Cocho de Juan, JA; Couce Pico, ML; Das, AM; de Baulny, HO; de Laet, C; Dionisi-Vici, C; Endig, J; Ernst, S; Freisinger, P; Gautschi, M; Gokcay, G; Hochuli, M; Jordan, J; Lotz-Havla, AS; Maiorana, A; Mandel, H; Mayorandan, S; McKiernan, P; Meyer, U; Moeslinger, D; Morlot, S; Sander, J; Santer, R; Scholl-Bürgi, S; Segarra, NG; Spiekerkoetter, U; Thimm, E; van Spronsen, F; Vogel, A; Zeman, J, 2014
)
0.4
" Nitisinone decreases homogentisic acid (HGA) in AKU but the dose-response relationship has not been previously studied."( Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid
Ayoob, H; Braconi, D; Briggs, MC; Bygott, H; Christensen, P; Cox, TF; Cronlund, A; Dutton, JJ; Fitzgerald, R; Gallagher, JA; Genovese, F; Hall, AK; Hughes, AT; Imrich, R; Jarvis, JC; Junestrand, C; Kullenberg, T; Laan, D; Le Quan Sang, KH; McCaffrey, J; Milan, AM; Nemethova, M; Olsson, B; Psarelli, EE; Ranganath, LR; Ross, G; Rovensky, J; Rudebeck, M; Santucci, A; Sireau, N; Svensson, L; Szamosi, J; Timmis, OG; van Kan, C; Zatkova, A, 2016
)
1.7
"Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1) was an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study."( Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid
Ayoob, H; Braconi, D; Briggs, MC; Bygott, H; Christensen, P; Cox, TF; Cronlund, A; Dutton, JJ; Fitzgerald, R; Gallagher, JA; Genovese, F; Hall, AK; Hughes, AT; Imrich, R; Jarvis, JC; Junestrand, C; Kullenberg, T; Laan, D; Le Quan Sang, KH; McCaffrey, J; Milan, AM; Nemethova, M; Olsson, B; Psarelli, EE; Ranganath, LR; Ross, G; Rovensky, J; Rudebeck, M; Santucci, A; Sireau, N; Svensson, L; Szamosi, J; Timmis, OG; van Kan, C; Zatkova, A, 2016
)
1.14
"A clear dose-response relationship was observed between nitisinone and the urinary excretion of HGA."( Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid
Ayoob, H; Braconi, D; Briggs, MC; Bygott, H; Christensen, P; Cox, TF; Cronlund, A; Dutton, JJ; Fitzgerald, R; Gallagher, JA; Genovese, F; Hall, AK; Hughes, AT; Imrich, R; Jarvis, JC; Junestrand, C; Kullenberg, T; Laan, D; Le Quan Sang, KH; McCaffrey, J; Milan, AM; Nemethova, M; Olsson, B; Psarelli, EE; Ranganath, LR; Ross, G; Rovensky, J; Rudebeck, M; Santucci, A; Sireau, N; Svensson, L; Szamosi, J; Timmis, OG; van Kan, C; Zatkova, A, 2016
)
1.03
" Therefore, the aims of this study were to investigate the variation and concentrations of 2-(2-nitro-4-trifluormethyl-benzyl)-1,3-cyclohexanedione (NTBC) during the day in relation to the detection of SA, while comparing different dosing regimens."( Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Burgerhof, JGM; Daly, A; de Blaauw, P; Heiner-Fokkema, MR; Kienstra, NS; MacDonald, A; McKiernan, PJ; van Dam, E; van Ginkel, WG; van Reemst, HE; van Spronsen, FJ, 2018
)
0.48
"026), although no significant difference in NTBC concentrations between different dosing regimens could be found (p = 0."( Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Burgerhof, JGM; Daly, A; de Blaauw, P; Heiner-Fokkema, MR; Kienstra, NS; MacDonald, A; McKiernan, PJ; van Dam, E; van Ginkel, WG; van Reemst, HE; van Spronsen, FJ, 2018
)
0.48
"NTBC could be less stable than previously considered, thus dosing NTBC once daily and lower concentrations may be less adequate."( Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Burgerhof, JGM; Daly, A; de Blaauw, P; Heiner-Fokkema, MR; Kienstra, NS; MacDonald, A; McKiernan, PJ; van Dam, E; van Ginkel, WG; van Reemst, HE; van Spronsen, FJ, 2018
)
0.48
"To study the efficacy of low dosage of nitisinone in alkaptonuria."( Efficacy of low dose nitisinone in the management of alkaptonuria.
Alqahtani, A; Blum, A; Feillet, F; Guéant, JL; Henn-Ménétré, S; Jeannesson, E; Merten, M; Renard, E; Sloboda, N; Wiedemann, A, 2019
)
1.1
"We described the evolution HGA excretion and tyrosine evolution in 3 AKU patients treated by very low dosage of nitisinone with regards to their daily protein intakes."( Efficacy of low dose nitisinone in the management of alkaptonuria.
Alqahtani, A; Blum, A; Feillet, F; Guéant, JL; Henn-Ménétré, S; Jeannesson, E; Merten, M; Renard, E; Sloboda, N; Wiedemann, A, 2019
)
1.04
" An inappropriate dosage of this therapeutic drug causes side effects; therefore, it is necessary to develop a rapid and sensitive method to monitor the content of NTBC in patients' blood."( β-Cyclodextrin Derivative Grafted on Silica Gel Represents a New Polymeric Sorbent for Extracting Nitisinone from Model Physiological Fluids.
Barchańska, H; Danek, M; Korytkowska-Wałach, A, 2021
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitorAn EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitor that interferes with the activity of 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
cyclohexanonesAny alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
mesotrioneAn aromatic ketone that is cyclohexa-1,3-dione in which one of the hydrogens at position 2 is substituted by a 4-(methanesulfonyl)-2-nitrobenzoyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Tyrosine metabolism and related disorders724

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency29.94390.001310.157742.8575AID1259252; AID1259253; AID1259256
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)Ki0.03700.03700.03700.0370AID1162498
4-hydroxyphenylpyruvate dioxygenase Rattus norvegicus (Norway rat)IC50 (µMol)0.04000.04000.04000.0400AID1480414
4-hydroxyphenylpyruvate dioxygenaseSus scrofa (pig)IC50 (µMol)0.04000.04003.02006.0000AID3446
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
tyrosine catabolic process4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
L-phenylalanine catabolic process4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
tyrosine catabolic process4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
4-hydroxyphenylpyruvate dioxygenase activity4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
protein homodimerization activity4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
metal ion binding4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytosol4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
extracellular exosome4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
Golgi membrane4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
endoplasmic reticulum membrane4-hydroxyphenylpyruvate dioxygenaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1480418Inhibition of Wistar rat liver cytosol HPPD using HPP as substrate assessed as reduction in O2 consumption2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1480437Effect on tyrosine level in plasma in human at 4 mg/kg, po (Rvb = 0.036 mM)2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1480439In vivo inhibition of HPPD in rat assessed as inhibition rate constant2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480414Inhibition of Wistar rat liver HPPD using 4-Hydroxyphenylpyruvate as substrate assessed as reduction in oxygen consumption preincubated for 3 mins followed by substrate addition2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480415Reversible inhibition of Wistar rat liver HPPD using 4-Hydroxyphenylpyruvate as substrate assessed activity recovery at 50 nM after 7 hrs2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480413Inhibition of Wistar rat liver HPPD using 4-Hydroxyphenylpyruvate as substrate assessed as reduction in oxygen consumption at 50 nM preincubated for 3 mins followed by substrate addition measured after 30 secs2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1480434In vivo inhibition of HPPD in rat assessed dissociation half life for enzyme-compound complex in plasma2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480440Effect on tyrosine level in plasma in human at 1 mg/kg, po under uncontrolled diet (Rvb = 0.076 mM)2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480441Effect on tyrosine level in plasma in human at 1 mg/kg, po up to 120 mins (Rvb = 0.076 mM)2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1162498Inhibition of purified His6-tagged recombinant human HPPD assessed as inhibition of maleylacetoacetate formation after 30 mins by UV/visible spectrophotometry2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Pyrazolone-quinazolone hybrids: a novel class of human 4-hydroxyphenylpyruvate dioxygenase inhibitors.
AID1480433In vivo inhibition of HPPD in human assessed dissociation half life for enzyme-compound complex in plasma2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480416Half life in rat2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID3446Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method2000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase.
AID1480432Half life in human at 4 mg/kg, po2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1480438Effect on tyrosine level in plasma in human at 4 mg/kg, po up to 2 days (Rvb = 0.036 mM)2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480412In vivo inhibition of Tyr hydroxylase in rat assessed as tyr concentration in plasma by colorimetric assay (Rvb = 0.1 mM)2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1480426Half life in human plasma at 4 mg/kg2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (238)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's25 (10.50)18.2507
2000's52 (21.85)29.6817
2010's119 (50.00)24.3611
2020's42 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.74 (24.57)
Research Supply Index5.54 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index96.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (4.96%)5.53%
Reviews34 (14.05%)6.00%
Case Studies40 (16.53%)4.05%
Observational3 (1.24%)0.25%
Other153 (63.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing of Nitisinone 10 mg Compared to the Reference Formulation Orfadin 10 mg in at Least 18 [NCT02750709]Phase 124 participants (Actual)Interventional2015-10-31Completed
Long-Term Clinical Trial of Nitisinone in Alkaptonuria [NCT00107783]Phase 240 participants (Actual)Interventional2005-01-31Completed
A Single Center, Single-Dose, Open-Label, Randomized Study to Compare the Bioavailability of an Oral Test Formulation Containing Nitisinone 10 mg in at Least 16 Healthy Male and Female Subjects Under Fasting and Fed Conditions [NCT02750332]Phase 120 participants (Actual)Interventional2015-11-30Completed
A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin Treatment in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care [NCT02320084]315 participants (Actual)Observational2013-09-30Completed
An Open-label, Non-randomized, 2-arm, 2-period Fixed Sequence Phase 1 Study to Evaluate the Potential Inhibition of Nitisinone on Cytochrome P450 2C9, 2D6, and 2E1 and the Organic Anion Transporters OAT1 and OAT3 in Healthy Volunteers [NCT03103568]Phase 136 participants (Actual)Interventional2017-03-28Completed
Prevention of Dichloroacetate Toxicity [NCT00031161]30 participants (Anticipated)Interventional2001-09-30Completed
An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 M [NCT01916382]Phase 3140 participants (Anticipated)Interventional2014-04-30Active, not recruiting
A Study to Evaluate the Bioequivalence of Orfadin Suspension 4 mg/mL Compared to Orfadin Capsules 10 mg, and the Effect of Food on the Bioavailability of the Suspension. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers [NCT01682538]Phase 112 participants (Actual)Interventional2012-08-31Completed
Orfadin and Nitinosine Study [NCT04113772]4 participants (Anticipated)Interventional2019-11-01Not yet recruiting
Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria [NCT01390077]Phase 2/Phase 38 participants (Actual)Interventional2011-01-31Completed
An International, Multicentre, Randomised, Open-label, No-treatment Controlled, Parallel-group, Dose-response Study to Investigate the Effect of Once Daily Nitisinone on 24-hour Urinary Homogentisic Acid Excretion in Patients With Alkaptonuria After 4 Wee [NCT01828463]Phase 240 participants (Actual)Interventional2013-05-31Completed
A Study to Evaluate the Bioequivalence of Orfadin Capsules 20 mg Compared to Orfadin Capsules 10 mg. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers. [NCT01857362]Phase 112 participants (Actual)Interventional2013-05-31Completed
A Pilot Study of Nitisinone in the Treatment of Oculocutaneous Albinism, Type 1B [NCT01838655]Phase 1/Phase 25 participants (Actual)Interventional2013-04-16Completed
Taste and Palatability of Orfadin Suspension. An Open, Non-controlled 3 Day Study in Pediatric Patients With Hereditary Tyrosinemia Type 1 Treated With Orfadin. [NCT01734889]Phase 118 participants (Actual)Interventional2012-10-31Completed
A Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing Nitisinone 10 mg Compared to Reference Formulation Orfadin In Healthy Subjects Under Fasting Conditions [NCT02750345]Phase 124 participants (Actual)Interventional2016-03-31Completed
Open-label, Multicentre, Multiple-dose Trial to Evaluate Pharmacokinetics, Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Orfadin in Patients Diagnosed With Hereditary Tyrosinemia Type 1 [NCT02323529]Phase 318 participants (Actual)Interventional2014-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00107783 (5) [back to overview]Change in 6 Minute Walk Test (6MWT)
NCT00107783 (5) [back to overview]Change in Functional Reach Assessment
NCT00107783 (5) [back to overview]Change in Schober's Test
NCT00107783 (5) [back to overview]Change in Timed Get up and go
NCT00107783 (5) [back to overview]Change in Total ROM Worse Hip
NCT01390077 (2) [back to overview]Homogentisic Acid Excretion
NCT01390077 (2) [back to overview]Tyrosine Levels
NCT01682538 (9) [back to overview]The Area Under the Serum Concentration Curve (AUC) During 72 Hours After Dose (AUC72h) During Fasting Conditions.
NCT01682538 (9) [back to overview]Oral Clearance (CL/F)
NCT01682538 (9) [back to overview]Terminal Half-life
NCT01682538 (9) [back to overview]The Area Under the Serum Concentration Curve (AUC) During 72 Hours After Dose (AUC72h)
NCT01682538 (9) [back to overview]The Maximum Serum Concentration (Cmax)
NCT01682538 (9) [back to overview]The Maximum Serum Concentration (Cmax) During Fasting Conditions.
NCT01682538 (9) [back to overview]Time to Reach C-Max (t-Max)
NCT01682538 (9) [back to overview]Apparent Volume of Distribution (Vz/F)
NCT01682538 (9) [back to overview]AUC From Time Zero to Infinity
NCT01734889 (5) [back to overview]The Palatability Scores on Day 2 (Subjects 5 - < 18 Years)
NCT01734889 (5) [back to overview]The Palatability Scores on Day 1 (Subjects 5 - < 18 Years)
NCT01734889 (5) [back to overview]The Acceptability Score for the Last Dose of the Suspension on Day 3 for Subjects < 5 Years
NCT01734889 (5) [back to overview]The Taste Score for the Last Dose of the Suspension on Day 3 for Subjects 5 - <18 Years
NCT01734889 (5) [back to overview]The Palatability Scores on Day 3 (Subjects 5 - < 18 Years)
NCT01838655 (53) [back to overview]Percent Change in Adjusted Melanin Index at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Hair Melanin at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Melanin Index at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Melanin Index at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Melanin Index at 6 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Melanin Index at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity Without Glare at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 12 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 3 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 6 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 9 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Number of Adverse Events Related to Investigational Product (IP)
NCT01838655 (53) [back to overview]Number of Non-ocular Adverse Events
NCT01838655 (53) [back to overview]Number of Ocular Adverse Events
NCT01838655 (53) [back to overview]Number of Participants Withdrawn From Investigational Product (IP) Due to Safety and Abnormal Laboratory Results
NCT01838655 (53) [back to overview]Absolute Change in Adjusted Melanin Index at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Adjusted Melanin Index at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Adjusted Melanin Index at 6 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Adjusted Melanin Index at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With High Glare at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With High Glare at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With High Glare at 6 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With High Glare at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With Medium Glare at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With Medium Glare at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With Medium Glare at 6 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity With Medium Glare at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Severity of Adverse Events
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity Without Glare at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity Without Glare at 6 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Contrast Sensitivity Without Glare at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Electronic Visual Acuity at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Electronic Visual Acuity at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Electronic Visual Acuity at 6 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Electronic Visual Acuity at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Electroretinogram (ERG) at Month 12 as Compared to Baseline.
NCT01838655 (53) [back to overview]Absolute Change in Electroretinogram (ERG) at Month 6 as Compared to Baseline.
NCT01838655 (53) [back to overview]Absolute Change in Hair Melanin at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Melanin Index at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Melanin Index at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Melanin Index at 6 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Melanin Index at 9 Months Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 12 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 3 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 6 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 9 Months as Compared to Baseline
NCT01838655 (53) [back to overview]Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 12 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.
NCT01838655 (53) [back to overview]Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 3 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.
NCT01838655 (53) [back to overview]Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 6 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.
NCT01838655 (53) [back to overview]Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 9 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.
NCT01838655 (53) [back to overview]Percent Change in Adjusted Melanin Index at 12 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Adjusted Melanin Index at 3 Months Compared to Baseline
NCT01838655 (53) [back to overview]Percent Change in Adjusted Melanin Index at 6 Months Compared to Baseline
NCT01857362 (2) [back to overview]The Maximum Serum Concentration (Cmax).
NCT01857362 (2) [back to overview]The Area Under the Serum Concentration vs. Time Profile During 72 Hours After Dose (AUC72h).
NCT02750332 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))
NCT02750332 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))
NCT02750332 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))
NCT02750332 (7) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT02750332 (7) [back to overview]Apparent Terminal Elimination Half-life (t1/2)
NCT02750332 (7) [back to overview]Time to Maximum Observed Plasma Concentration (Tmax)
NCT02750332 (7) [back to overview]Terminal Elimination Rate Constant (λz)
NCT02750345 (7) [back to overview]Apparent Terminal Elimination Half-life (t1/2)
NCT02750345 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))
NCT02750345 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))
NCT02750345 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))
NCT02750345 (7) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT02750345 (7) [back to overview]Terminal Elimination Rate Constant (λz)
NCT02750345 (7) [back to overview]Time to Maximum Observed Plasma Concentration (Tmax)
NCT02750709 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 120 Hours Post-dose (AUC(0-120))
NCT02750709 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 72 Hours Post-dose (AUC(0-72))
NCT02750709 (7) [back to overview]Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞)
NCT02750709 (7) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT02750709 (7) [back to overview]Terminal Elimination Rate Constant (λz)
NCT02750709 (7) [back to overview]Time to Maximum Observed Plasma Concentration (Tmax)
NCT02750709 (7) [back to overview]Apparent Terminal Half-life (t1/2)

Change in 6 Minute Walk Test (6MWT)

Change from baseline of the 6MWT at 36 months. The 6MWT measures the distance that a patient can quickly walk on a flat hard surface in a period of six minutes. (NCT00107783)
Timeframe: Measured at baseline and at 36 months

Interventionft (Mean)
Control22
Nitisinone-treated169

[back to top]

Change in Functional Reach Assessment

Change from baseline of functional reach assessment at 36 months. Functional reach assessment measures the difference between the length of a person's outstretched arm and their maximal reach forward, while maintaining balance. (NCT00107783)
Timeframe: Measured at baseline and at 36 months

Interventioncm (Mean)
Control-1.21
Nitisinone-treated-1.86

[back to top]

Change in Schober's Test

Change from baseline of Schober's test at 36 months. Schober's test measures a patient's ability to flex his/her lower back. The examiner makes a mark at L5 (fifth lumbar vertebra) and places one finger 5 cm below and another finger 10 cm above this mark. The patient is asked to touch his/her toes. The examiner measures the increase in distance between the two fingers. (NCT00107783)
Timeframe: Measured at baseline and at 36 months

Interventioncm (Mean)
Control-0.06
Nitisinone-treated0.12

[back to top]

Change in Timed Get up and go

Change from baseline of timed get up and go at 36 months. In timed get up and go, the patient is asked to stand up from a standard chair and walk a distance of 3 meters, turn around and walk back to the chair and sit down. The examiner measures the time it takes for the patient to perform this series of tasks. (NCT00107783)
Timeframe: Measured at baseline and at 36 months

Interventionseconds (Mean)
Control-0.54
Nitisinone-treated-1.33

[back to top]

Change in Total ROM Worse Hip

Change from baseline in the total (external + internal) hip range of motion (ROM) in the worse hip at 36 months. The patient lies on exam table in the supine position. The patient flexes his/her hip and knee to 90 degrees. The examiner measures the patient's hip external rotation and hip internal rotation range of motion with a goniometer. (NCT00107783)
Timeframe: Measured at baseline and at 36 months

Interventiondegrees (Mean)
Control-9.1
Nitisinone-treated1.6

[back to top]

Homogentisic Acid Excretion

Urine homogentisic acid (umol/mmol creatinine) (NCT01390077)
Timeframe: 3-6 months

InterventionuM (Mean)
HGA, Baseline1425.9
HGA, 2 mg/d Nitisinone113.1
HGA, 4 mg Nitisinone34.0

[back to top]

Tyrosine Levels

Plasma tyrosine (uM) (NCT01390077)
Timeframe: 3-6 months

InterventionuM (Mean)
Tyrosine, Baseline53.1
Tyrosine, 2 mg/d Nitisinone668.7
Tyrosine, 4 mg Nitisinone703.7

[back to top]

The Area Under the Serum Concentration Curve (AUC) During 72 Hours After Dose (AUC72h) During Fasting Conditions.

(NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

InterventionuM*h (Geometric Mean)
Orfadin Capsules, Fasting403
Orfadin Suspension, Fasting346

[back to top]

Oral Clearance (CL/F)

Measured for the Orfadin capsules and suspension treatments arms - both fasting and with food. (NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

InterventionL/h (Median)
Orfadin Capsules, Fasting0.145
Orfadin Suspension, Fasting0.160
Orfadin Suspension, With Food0.158

[back to top]

Terminal Half-life

Measured for the Orfadin capsules and suspension treatments arms - both fasting and with food. (NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

Interventionhours (Median)
Orfadin Capsules, Fasting48.7
Orfadin Suspension, Fasting53.6
Orfadin Suspension, With Food54.3

[back to top]

The Area Under the Serum Concentration Curve (AUC) During 72 Hours After Dose (AUC72h)

Measured for the Orfadin suspension treatments arms- both fasting and with food. (NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

InterventionuM*h (Geometric Mean)
Orfadin Suspension, Fasting346
Orfadin Suspension, With Food350

[back to top]

The Maximum Serum Concentration (Cmax)

Measured for the Orfadin suspension treatment arms- both fasting and with food. (NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

InterventionnM (Geometric Mean)
Orfadin Suspension, Fasting9741
Orfadin Suspension, With Food7808

[back to top]

The Maximum Serum Concentration (Cmax) During Fasting Conditions.

(NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

InterventionnM (Geometric Mean)
Orfadin Capsules, Fasting10213
Orfadin Suspension, Fasting9741

[back to top]

Time to Reach C-Max (t-Max)

Measured for the Orfadin capsules and suspension treatments arms - both fasting and with food. (NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

Interventionhours (Median)
Orfadin Capsules, Fasting3.50
Orfadin Suspension, Fasting0.38
Orfadin Suspension, With Food8.00

[back to top]

Apparent Volume of Distribution (Vz/F)

Measured for the Orfadin capsules and suspension treatments arms - both fasting and with food. (NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

InterventionL (Median)
Orfadin Capsules, Fasting9.80
Orfadin Suspension, Fasting12.2
Orfadin Suspension, With Food12.8

[back to top]

AUC From Time Zero to Infinity

Measured for the Orfadin capsules and suspension treatments arms - both fasting and with food. (NCT01682538)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose.

Interventionh*uM (Geometric Mean)
Orfadin Capsules, Fasting633
Orfadin Suspension, Fasting559
Orfadin Suspension, With Food577

[back to top]

The Palatability Scores on Day 2 (Subjects 5 - < 18 Years)

Patients rated the palatability of the suspension. The following grading was applied: 5 (very good), 4 (good), 3 (neither good nor bad), 2 (bad) and 1 (very bad). (NCT01734889)
Timeframe: Day 2

Interventionunits on a scale (Median)
Age 5-<18 Years4.0

[back to top]

The Palatability Scores on Day 1 (Subjects 5 - < 18 Years)

Patients rated the palatability of the suspension. The following grading was applied: 5 (very good), 4 (good), 3 (neither good nor bad), 2 (bad) and 1 (very bad). (NCT01734889)
Timeframe: Day 1

Interventionunits on a scale (Median)
Age 5-<18 Years4.0

[back to top]

The Acceptability Score for the Last Dose of the Suspension on Day 3 for Subjects < 5 Years

The parents of patients aged <5 years rated their child´s acceptability of the suspension. The following grading was applied: 5 (very well), 4 (well), 3 (neither well nor badly), 2 (badly) and 1 (very badly). (NCT01734889)
Timeframe: Day 3

Interventionunits on a scale (Median)
Age <5 Years5.0

[back to top]

The Taste Score for the Last Dose of the Suspension on Day 3 for Subjects 5 - <18 Years

Patients rated the taste of the suspension. The following grading was applied: 5 (very good taste), 4 (good taste), 3 (neither good nor bad taste), 2 (bad taste) and 1 (very bad taste). (NCT01734889)
Timeframe: Day 3

Interventionunits on a scale (Median)
Age 5-<18 Years4.0

[back to top]

The Palatability Scores on Day 3 (Subjects 5 - < 18 Years)

Patients rated the palatability of the suspension. The following grading was applied: 5 (very good), 4 (good), 3 (neither good nor bad), 2 (bad) and 1 (very bad). (NCT01734889)
Timeframe: Day 3

Interventionunits on a scale (Median)
Age 5-<18 Years4.0

[back to top]

Percent Change in Adjusted Melanin Index at 9 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 9 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone33.294.539.681.06.0

[back to top]

Percent Change in Hair Melanin at 12 Months Compared to Baseline

Hair melanin was assessed using pyrrole-2,3,5-tricarboxylic acid (PTCA), a marker of eumelanin and 4-amino-3-hydroxyphenylalanine (4-AHP), a marker of pheomelanin. (NCT01838655)
Timeframe: Baseline and 12 months

Interventionpercentage change (Mean)
PTCA4-AHP
Nitisinone50.3027.23

[back to top]

Percent Change in Melanin Index at 12 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 12 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone14.710.910.210.413.3

[back to top]

Percent Change in Melanin Index at 3 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 3 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone15.06.72.88.618.9

[back to top]

Percent Change in Melanin Index at 6 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 6 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone8.412.717.010.219.2

[back to top]

Percent Change in Melanin Index at 9 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 9 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone9.28.915.89.58.8

[back to top]

Absolute Change in Contrast Sensitivity Without Glare at 12 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. The minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity without glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 12 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 12 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone2.42.01.81.60.6

[back to top]

Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 12 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 12 months; these mean grades were then used to calculate percentage change from baseline. (NCT01838655)
Timeframe: Baseline and 12 months

Interventionpercentage change (Mean)
ODOS
Nitisinone77.767.0

[back to top]

Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 3 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 3 months; these mean grades were then used to calculate percentage change from baseline. (NCT01838655)
Timeframe: Baseline and 3 months

Interventionpercentage change (Mean)
ODOS
Nitisinone66.729.0

[back to top]

Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 6 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 6 months; these mean grades were then used to calculate percentage change from baseline. (NCT01838655)
Timeframe: Baseline and 6 months

Interventionpercentage change (Mean)
ODOS
Nitisinone23.34.0

[back to top]

Percent Change in Semi-quantitative Iris Pigmentation for Each Eye at 9 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 9 months; these mean grades were then used to calculate percentage change from baseline. (NCT01838655)
Timeframe: Baseline and 9 months

Interventionpercentage change (Mean)
ODOS
Nitisinone42.034.0

[back to top] [back to top]

Number of Non-ocular Adverse Events

(NCT01838655)
Timeframe: Study duration, up to 18 months

Interventionnon-ocular adverse events (Number)
Nitisinone10

[back to top]

Number of Ocular Adverse Events

(NCT01838655)
Timeframe: Study duration, up to 18 months

Interventionocular adverse events (Number)
Nitisinone0

[back to top]

Number of Participants Withdrawn From Investigational Product (IP) Due to Safety and Abnormal Laboratory Results

(NCT01838655)
Timeframe: Study duration, up to 18 months

Interventionparticipant withdrawals (Number)
Nitisinone0

[back to top]

Absolute Change in Adjusted Melanin Index at 12 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 12 Months

InterventionAdjusted Melanin Index*10^-5 (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone8.37.04.26.88.6

[back to top]

Absolute Change in Adjusted Melanin Index at 3 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 3 Months

InterventionAdjusted Melanin Index*10^-5 (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone16.44.820.910.710.6

[back to top]

Absolute Change in Adjusted Melanin Index at 6 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 6 Months

InterventionAdjusted Melanin Index*10^-5 (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone11.88.29.312.112.6

[back to top]

Absolute Change in Adjusted Melanin Index at 9 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 9 Months

InterventionAdjusted Melanin Index*10^-5 (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone10.39.45.511.61.5

[back to top]

Absolute Change in Contrast Sensitivity With High Glare at 12 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with high glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 12 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 12 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.62.22.61.80.0

[back to top]

Absolute Change in Contrast Sensitivity With High Glare at 3 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with high glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 3 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 3 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.21.80.20.20.0

[back to top]

Absolute Change in Contrast Sensitivity With High Glare at 6 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with high glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 6 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 6 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.01.61.20.40.0

[back to top]

Absolute Change in Contrast Sensitivity With High Glare at 9 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with high glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 9 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 9 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.40.61.01.60.6

[back to top]

Absolute Change in Contrast Sensitivity With Medium Glare at 12 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with medium glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 12 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 12 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.41.82.60.41.2

[back to top]

Absolute Change in Contrast Sensitivity With Medium Glare at 3 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with medium glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 3 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 3 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.40.43.60.20.6

[back to top]

Absolute Change in Contrast Sensitivity With Medium Glare at 6 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with medium glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 6 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 6 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone2.41.41.80.40.6

[back to top]

Absolute Change in Contrast Sensitivity With Medium Glare at 9 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. Minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity with medium glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 9 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 9 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone2.01.21.00.60.8

[back to top]

Severity of Adverse Events

(NCT01838655)
Timeframe: Study duration, up to 18 months

Interventionadverse events (Number)
MildModerate
Nitisinone91

[back to top]

Absolute Change in Contrast Sensitivity Without Glare at 3 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. The minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity without glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 3 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 3 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.60.80.41.20.6

[back to top]

Absolute Change in Contrast Sensitivity Without Glare at 6 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. The minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity without glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 6 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 6 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone2.00.21.62.80.0

[back to top]

Absolute Change in Contrast Sensitivity Without Glare at 9 Months Compared to Baseline

Gratings, images with alternating light and dark bars, assess contrast sensitivity via spatial frequency and contrast. Spatial frequency (SF), the number of pairs of bars (1 light, 1 dark) imaged within a given distance of the retina, is measured as the number of cycles per degree (cpd) of visual angle, where a cycle is 1 pair of bars. Grating of high SF corresponds to narrow bars; grating of low SF corresponds to wide bars. Contrast is the intensity difference between light and dark bars. The minimum contrast required to detect a given SF is the threshold contrast. The lower the threshold contrast, higher the contrast sensitivity. Contrast sensitivity without glare was measured at frequencies of 1.5, 3, 6, 12, 18 cpd. Absolute change from baseline to 9 months was calculated. Raw values were used for the planned descriptive analysis; logarithmic transformation was not used as formal statistical analysis was not planned and was not appropriate as a majority of the raw values were 0. (NCT01838655)
Timeframe: Baseline and 9 months

Interventionunits (Mean)
Frequency 1.5Frequency 3Frequency 6Frequency 12Frequency 18
Nitisinone1.80.61.01.40.0

[back to top]

Absolute Change in Electronic Visual Acuity at 12 Months Compared to Baseline

Visual acuity was measured using the Electronic ETDRS Visual Acuity Testing protocol. Acuity is measured as letters read using an electronic ETDRS program. (NCT01838655)
Timeframe: Baseline and 12 months

InterventionETDRS letters (Mean)
ODOS
Nitisinone5.45.0

[back to top]

Absolute Change in Electronic Visual Acuity at 3 Months Compared to Baseline

Visual acuity was measured using the Electronic ETDRS Visual Acuity Testing protocol. Acuity is measured as letters read using an electronic ETDRS program. (NCT01838655)
Timeframe: Baseline and 3 months

InterventionETDRS letters (Mean)
ODOS
Nitisinone1.86.0

[back to top]

Absolute Change in Electronic Visual Acuity at 6 Months Compared to Baseline

Visual acuity was measured using the Electronic ETDRS Visual Acuity Testing protocol. Acuity is measured as letters read using an electronic ETDRS program. (NCT01838655)
Timeframe: Baseline and 6 months

InterventionETDRS letters (Mean)
ODOS
Nitisinone4.24.8

[back to top]

Absolute Change in Electronic Visual Acuity at 9 Months Compared to Baseline

Visual acuity was measured using the Electronic ETDRS Visual Acuity Testing protocol. Acuity is measured as letters read using an electronic ETDRS program. (NCT01838655)
Timeframe: Baseline and 9 months

InterventionETDRS letters (Mean)
ODOS
Nitisinone2.85.6

[back to top]

Absolute Change in Electroretinogram (ERG) at Month 12 as Compared to Baseline.

Amplitude for the ERG parameter, Dark Adaptation (DA) Comb B, was measured at each visit. Participants left and right eye will be analyzed. (NCT01838655)
Timeframe: Baseline and 12 months

InterventionµV (Mean)
ODOS
Nitisinone27.885.8

[back to top]

Absolute Change in Electroretinogram (ERG) at Month 6 as Compared to Baseline.

Amplitude for the ERG parameter, Dark Adaptation (DA) Comb B, was measured at each visit. Participants left and right eye will be analyzed. (NCT01838655)
Timeframe: Baseline and 6 months

InterventionµV (Mean)
ODOS
Nitisinone38.676.2

[back to top]

Absolute Change in Hair Melanin at 12 Months Compared to Baseline

Hair melanin was assessed using pyrrole-2,3,5-tricarboxylic acid (PTCA), a marker of eumelanin and 4-amino-3-hydroxyphenylalanine (4-AHP), a marker of pheomelanin. (NCT01838655)
Timeframe: Baseline and 12 months

Interventionng/mg (Mean)
PTCA4-AHP
Nitisinone8.385.92

[back to top]

Absolute Change in Melanin Index at 12 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 12 Months

InterventionMelanin Index (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone3.72.32.02.23.4

[back to top]

Absolute Change in Melanin Index at 3 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 3 Months

InterventionMelanin Index (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone3.81.40.61.84.5

[back to top]

Absolute Change in Melanin Index at 6 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 6 Months

InterventionMelanin Index (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone2.22.73.32.14.4

[back to top]

Absolute Change in Melanin Index at 9 Months Compared to Baseline

"Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Melanin (M) index was calculated as follows:~Eqn 1= [ (PR at 650nm + PR at 660nm + 0.5*PR at 640nm + 0.5*PR at 670nm)/3 ]/100; M index = 100*log (1/Eqn 1) Higher values of M index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites:forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Absolute change from baseline was calculated using these mean values." (NCT01838655)
Timeframe: Baseline and 9 Months

InterventionMelanin Index (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone2.41.93.22.12.2

[back to top]

Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 12 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 12 months; these mean grades were then used to calculate absolute change from baseline. (NCT01838655)
Timeframe: Baseline and 12 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone1.41.2

[back to top]

Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 3 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 3 months; these mean grades were then used to calculate absolute change from baseline. (NCT01838655)
Timeframe: Baseline and 3 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone1.20.6

[back to top]

Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 6 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 6 months; these mean grades were then used to calculate absolute change from baseline. (NCT01838655)
Timeframe: Baseline and 6 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone0.40.1

[back to top]

Absolute Change in Semi-quantitative Iris Pigmentation for Each Eye at 9 Months as Compared to Baseline

In Adobe Photoshop 7.0 the high resolution slit lamp image was divided into 4 quadrants with vertical and horizontal lines transecting the center of the iris. Using the elliptical marquee tool, a circle, approximately 0.25 times the diameter of the iris, was drawn in the center of each quadrant. Gaussian blur with radius of 50 was applied to the area enclosed in the 4 circles. With the dropper tool, the red pigment value corresponding to the degree of iris transillumination was sampled at the center of each circle. The 4 values were averaged to yield a composite transillumination score for each subject. Quantified values were then correlated to a scale score from 1 to 8 to generate an 8-point iris transillumination scale, with lower scores reflective of greater iris pigmentation (melanin content). The mean score across the 2 images for each participant's eye was calculated at baseline and 9 months; these mean grades were then used to calculate absolute change from baseline. (NCT01838655)
Timeframe: Baseline and 9 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone0.80.7

[back to top]

Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 12 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.

"High-resolution (2544x1696) digital images of the anterior segment of both eyes were captured prior to pupil dilation using diffuse illumination and iris transillumination. An independent reviewer selected two transillumination images from each eye of each participant for each visit according to preset quality criteria. Images were coded, randomized and presented to a panel of 18 graders on a SHARP 90 HD LED TV. After instruction and a practice dataset, graders scored each image using an 8-point scale. Graders could score images with a single decimal place if they felt an image fell in between two of the standards. The iris transillumination scale ranged from 0 to 8, with lower scores reflective of greater iris pigmentation (melanin content). The mean across all graders and the two images for each participant's eye at baseline and 12 months was calculated; these mean grades were then used to calculate absolute change from baseline at 12 months." (NCT01838655)
Timeframe: Baseline and 12 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone1.20.9

[back to top]

Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 3 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.

"High-resolution (2544x1696) digital images of the anterior segment of both eyes were captured prior to pupil dilation using diffuse illumination and iris transillumination. An independent reviewer selected two transillumination images from each eye of each participant for each visit according to preset quality criteria. Images were coded, randomized and presented to a panel of 18 graders on a SHARP 90 HD LED TV. After instruction and a practice dataset, graders scored each image using an 8-point scale. Graders could score images with a single decimal place if they felt an image fell in between two of the standards. The iris transillumination scale ranged from 0 to 8, with lower scores reflective of greater iris pigmentation (melanin content). The mean across all graders and the two images for each participant's eye at baseline and 3 months was calculated; these mean grades were then used to calculate absolute change from baseline at 3 months." (NCT01838655)
Timeframe: Baseline and 3 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone0.80.9

[back to top]

Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 6 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.

"High-resolution (2544x1696) digital images of the anterior segment of both eyes were captured prior to pupil dilation using diffuse illumination and iris transillumination. An independent reviewer selected two transillumination images from each eye of each participant for each visit according to preset quality criteria. Images were coded, randomized and presented to a panel of 18 graders on a SHARP 90 HD LED TV. After instruction and a practice dataset, graders scored each image using an 8-point scale. Graders could score images with a single decimal place if they felt an image fell in between two of the standards. The iris transillumination scale ranged from 0 to 8, with lower scores reflective of greater iris pigmentation (melanin content). The mean across all graders and the two images for each participant's eye at baseline and 6 months was calculated; these mean grades were then used to calculate absolute change from baseline at 6 months." (NCT01838655)
Timeframe: Baseline and 6 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone0.60.4

[back to top]

Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 9 Months as Compared to Baseline. Participants Left and Right Eyes Will be Analyzed.

"High-resolution (2544x1696) digital images of the anterior segment of both eyes were captured prior to pupil dilation using diffuse illumination and iris transillumination. An independent reviewer selected two transillumination images from each eye of each participant for each visit according to preset quality criteria. Images were coded, randomized and presented to a panel of 18 graders on a SHARP 90 HD LED TV. After instruction and a practice dataset, graders scored each image using an 8-point scale. Graders could score images with a single decimal place if they felt an image fell in between two of the standards. The iris transillumination scale ranged from 0 to 8, with lower scores reflective of greater iris pigmentation (melanin content). The mean across all graders and the two images for each participant's eye at baseline and 9 months was calculated; these mean grades were then used to calculate absolute change from baseline at 9 months." (NCT01838655)
Timeframe: Baseline and 9 months

Interventionscores on a scale (Mean)
ODOS
Nitisinone0.90.6

[back to top]

Percent Change in Adjusted Melanin Index at 12 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 12 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone24.7104.532.747.430.5

[back to top]

Percent Change in Adjusted Melanin Index at 3 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 3 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone50.140.1201.083.342.1

[back to top]

Percent Change in Adjusted Melanin Index at 6 Months Compared to Baseline

Microflash 200D is a diffuse reflectance spectrophotometer that uses a prism photodiode to provide information at 10 nm increments along the visual spectrum from 400 to 700 nm. Percent reflectance (PR) at a specific wavelength was placed into context by relating it to the reflectance of a blank at the equivalent wavelength (i.e. relating the object's reflectance to the maximum reflectance possible). Apparent absorbance (AA) at a given wavelength was determined as log10 (PR of blank/PR of object) at that wavelength. Adjusted Melanin (AM) index is calculated as the slope of AA levels from 650 to 700 nm. Lower values of AM index correspond to higher melanin concentrations. Measurements were collected 5 times at each visit from each of the following sites: forehead, inner forearm, outer forearm, inner bicep and lower back. The mean of these five measurements was calculated at each visit. Percent change from baseline was calculated using these mean values. (NCT01838655)
Timeframe: Baseline and 6 Months

InterventionPercentage change (Mean)
ForeheadInner BicepLower BackInner ForearmOuter Forearm
Nitisinone35.4123.0117.491.167.9

[back to top]

The Maximum Serum Concentration (Cmax).

(NCT01857362)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose

InterventionnM (Geometric Mean)
Nitisinone 2 x 10 mg Capsules6438
Nitisinone 1 x 20 mg Capsules6366

[back to top]

The Area Under the Serum Concentration vs. Time Profile During 72 Hours After Dose (AUC72h).

(NCT01857362)
Timeframe: Day 1 predose and at 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose

InterventionuM*h (Geometric Mean)
Nitisinone 2 x 10 mg Capsules262
Nitisinone 1 x 20 mg Capsules267

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))

(NCT02750332)
Timeframe: 0 - 120 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Test Product (Fasted)71441.92
Test Product (Fed)67242.59

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))

(NCT02750332)
Timeframe: 0 - 72 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Test Product (Fasted)52976.29
Test Product (Fed)49762.02

[back to top]

Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))

(NCT02750332)
Timeframe: 0 - 120 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Test Product (Fasted)100007.01
Test Product (Fed)90749.55

[back to top]

Maximum Observed Plasma Concentration (Cmax)

(NCT02750332)
Timeframe: 0 - 120 hours post-dose

Interventionng/mL (Geometric Mean)
Test Product (Fasted)1168.23
Test Product (Fed)1054.32

[back to top]

Apparent Terminal Elimination Half-life (t1/2)

(NCT02750332)
Timeframe: 0 - 120 hours post-dose

Interventionhr (Geometric Mean)
Test Product (Fasted)64.40
Test Product (Fed)59.22

[back to top]

Time to Maximum Observed Plasma Concentration (Tmax)

(NCT02750332)
Timeframe: 0 - 120 hours post-dose

Interventionhr (Median)
Test Product (Fasted)3.00
Test Product (Fed)6.00

[back to top]

Terminal Elimination Rate Constant (λz)

(NCT02750332)
Timeframe: 0 - 120 hours post-dose

Intervention1/hr (Geometric Mean)
Test Product (Fasted)0.011
Test Product (Fed)0.012

[back to top]

Apparent Terminal Elimination Half-life (t1/2)

(NCT02750345)
Timeframe: 0 - 120 hours post-dose

Interventionhr (Geometric Mean)
Treatment Period 158.668
Treatment Period 260.780
Reference Product59.904

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))

(NCT02750345)
Timeframe: 0 - 120 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Treatment Period 177874.13
Treatment Period 277295.02
Reference Product78672.56

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))

(NCT02750345)
Timeframe: 0 - 72 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Treatment Period 157838.41
Treatment Period 257497.79
Reference Product59013.52

[back to top]

Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))

(NCT02750345)
Timeframe: 0 - 120 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Treatment Period 1104495.96
Treatment Period 2105117.79
Reference Product106892.31

[back to top]

Maximum Observed Plasma Concentration (Cmax)

(NCT02750345)
Timeframe: 0 - 120 hours post-dose

Interventionng/mL (Geometric Mean)
Test Product 11277.77
Test Product 21272.34
Reference Product1339.79

[back to top]

Terminal Elimination Rate Constant (λz)

(NCT02750345)
Timeframe: 0 - 120 hours post-dose

Intervention1/hr (Geometric Mean)
Treatment Period 10.012
Treatment Period 20.011
Reference Product0.012

[back to top]

Time to Maximum Observed Plasma Concentration (Tmax)

(NCT02750345)
Timeframe: 0 - 120 hours post-dose

Interventionhr (Median)
Treatment Period 13.5
Treatment Period 24.0
Reference Product2.5

[back to top]

Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 120 Hours Post-dose (AUC(0-120))

(NCT02750709)
Timeframe: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours

Interventionhr*ng/mL (Geometric Mean)
Treatment Period 166220.91
Treatment Period 261883.52
Reference Product66199.76

[back to top]

Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 72 Hours Post-dose (AUC(0-72))

(NCT02750709)
Timeframe: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Treatment Period 149448.49
Treatment Period 246401.12
Reference Product49582.69

[back to top]

Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞)

(NCT02750709)
Timeframe: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours

Interventionhr*ng/mL (Geometric Mean)
Treatment Period 191226.27
Treatment Period 283245.33
Reference Product89394.35

[back to top]

Maximum Observed Plasma Concentration (Cmax)

(NCT02750709)
Timeframe: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours

Interventionng/mL (Geometric Mean)
Treatment Period 11137.40
Treatment Period 21080.69
Reference Product1168.71

[back to top]

Terminal Elimination Rate Constant (λz)

(NCT02750709)
Timeframe: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours

Intervention1/hr (Geometric Mean)
Treatment Period 10.011
Treatment Period 20.012
Reference Product0.012

[back to top]

Time to Maximum Observed Plasma Concentration (Tmax)

(NCT02750709)
Timeframe: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours

Interventionhr (Median)
Treatment Period 13.00
Treatment Period 23.00
Reference Product2.50

[back to top]

Apparent Terminal Half-life (t1/2)

(NCT02750709)
Timeframe: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours

Interventionhr (Geometric Mean)
Treatment Period 161.42
Treatment Period 258.41
Reference Product59.43

[back to top]